In CommitteeFiled Mar 17, 2026
Sponsor: Rep. Sessions, Pete [R-TX-17] (R)
Latest Action
Referred to the House Committee on Energy and Commerce.
Mar 17, 2026
Summary
The FAIR Act lets the FDA grant marketing approval to medicines that are already authorized by trusted foreign regulators when they treat an immediately life‑threatening condition. Sponsors submit a request and, if the criteria are met, the agency must decide within 30 days. The goal is to give U.S. patients quicker access to innovative therapies while maintaining safety oversight.
AI-generated summary — may be incomplete or inaccurate. Verify against the official bill text.
Track this bill
Get real-time alerts when HR 7953 changes status, plus AI-powered summaries and stage predictions.
Sign up free